ForteBio will provide a range of innovative, label-free protein analysis instruments that will extend Pall’s capabilities in the biopharmaceuticals process monitoring market and in the protein research market.
ForteBio’s portfolio of analytical solutions will enable researchers to measure proteins in real time without the aid of fluorescent, radio or calorimetric labels or markers that can contaminate samples.
Through this, characterization of drug candidates becomes easier and faster there by enabling an improvement in the process development and speed time to market.
The deal is expected to close by February 2012 and the financial terms of the deal have not been revealed.